Summary Gene amplification is a mechanism whereby cultured animal cells and human tumours become resistant to cancer chemotherapeutic agents. This review of studies from the authors' laboratory describes properties of the acquisition of resistance to methotrexate in cultured mammalian cells by virtue of amplification of the dihydrofolate reductase gene. These properties result in a heterogeneous cell population with respect to many cell properties, including the number and stability of the amplified genes. Gene amplification results from overreplication of DNA in a single cell cycle as a result of inhibition of DNA synthesis. The cells surviving such overreplication constitute a heterogeneous population with multiple chromosomal changes, including partial or complete endoreduplication of chromosomes, as well as a variety of chromosomal rearrangements. A similar phenomenon may underlie the generation of aneuploidy in tumours, their malignant progression, and the generation of heterogeneity in the tumour cell population.
The heterogeneity in properties of cells in many tumours, in particular solid tumours, is a well documented phenomenon. One such phenomenon is resistance to chemotherapeutic agents. This paper will review studies from the authors' laboratory concerning the acquisition of resistance to methotrexate (MTX) as a consequence of amplification of the dihydrofolate reductase (DHFR) gene, and will emphasize those aspects of amplification events that result in marked heterogeneity in cell populations. Gene amplification, which involves overreplication of DNA in a single cell cycle, results in a wide variety of chromosomal rearrangements, and may be a mechanism that produces heterogeneity in cell properties in a variety of solid tumour cell populations. The interested reader is referred to Schimke (1984a) for a review of the subject of gene amplification in somatic cells. For the more clinically inclined, the problem of clinical emergence of resistance is discussed by Schimke (1984b) .
Properties of dihydrofolate reductase gene amplification Three mechanisms have been described for acquisition of resistance in cells grown continuously *Delivered at the Joint Meeting of the British Association for Cancer Research at the Royal Society of Medicine (Section of Oncology), Nov. 22-23, 1984. Correspondence: R.T. Schimke. Received 18 December 1984. in MTX: (1) alteration in affinity of MTX for DHFR (Haber et al., 1981) ; (2) altered transport of MTX (Sirotnak et al., 1981) ; (3) (Beidler & Spengler, 1976; Nunberg et al., 1978) . When the genes are unstable, they reside on extrachromosomal elements called minute chromosomes. Such elements replicate in the cell cycle, but do not contain centromeric regions; hence they can undergo micronucleation and unequal distribution into daughter cells at mitosis, resulting in their instability (Mariani & Schimke, 1984) and the chromosomal localization of rereplicated genes is the consequence of secondary recombination events. If the overreplicated DNA recombines to form a circular structure (Hamkalo et al., 1985) it will constitute an extrachromosomal minute chromosome. If, as a postulated rarer event, the overreplicated DNA recombines into the chromosome, this would result in amplification at the site of the resident (non-amplified) gene (see Schimke et al., 1981 , Schimke, 1984a for detailed discussions). Cell populations, therefore, will be vastly heterogeneous with respect to both the number and localization of amplified genes (see for examples of such heterogeneity).
4. The same MTX resistance phenotype can result from amplification of two different DNA sequences. In Leishmania tropica we have found that resistance can occur by virtue of amplification of two completely different DNA sequences (Beverley et al., 1984) . Such variability in the molecular events resulting in the same phenotype constitutes an additional form of heterogeneity in cells.
5. MTX resistance resulting from DHFR gene amplification occurs in instances of clinical importance, i.e. cells obtained from patients treated with MTX (Curd et al., 1983; Horns et al., 1984; Trent et al., 1984; Carman et al., 1984) .
6. The spontaneous frequency of gene amplification in cultured animal cells is extremely high. As studied under non-selective conditions, and employing the fluorescence activated cell sorter, the frequency of amplification of the DHFR gene is 10-3 events per cell generation (Johnson et al., 1983) . This frequency is 102 higher than frequencies estimated by clonal methods employing MTX selection conditions Tlsty et al., 1984) because the fluorescence cell sorter is a much more sensitive means of detecting small changes in DHFR gene copy number than are the clonal selection methods.
7. The frequency of DHFR gene amplification can be increased dramatically by a variety of agents that inhibit reversibly DNA synthesis, including MTX (Tlsty et al., 1982) , hydroxyurea , UV light and the carcinogen N-acetoxy N-acetylaminofluorene (Tlsty et al., 1984) . Although many of these agents produce "damage" in DNA, among their consequences is inhibition of DNA synthesis current findings in the laboratory suggest that it is the property of reversible inhibition of DNA synthesis that is important in the generation of gene amplification (see below).
8. Gene amplification is a common phenomenon in biology and is being reported increasingly in somatic cells. Amplification has been reported for a number of specific genes, including CAD (Wahl et al., 1979) , metallothionine (Beach & Palmiter, 1981) , Hydroxymethylglutaryl CoA reductase (Chin et al., 1982) , adenosine deaminase (Yeung et al., 1983) , glutamine synthetase (Young & Ringold, 1983) , ornithine decarboxylase (McConlogue et al., 1984) , and UMP synthetase (Kanalas & Suttle, 1984) . In addition a number of investigators have reported a transport cross-resistance to a number of alkaloids with overproduction of one or more proteins and karyological and molecular evidence of gene amplification (Roninson et al., 1984) . There are some 10-15 other examples of gene amplification in somatic cells not listed here. Suffice it to indicate that such amplification events occur readily in somatic cells (see Stark & Wahl, 1984) .
On the mechanism ofgene amplification Studies in our laboratory have concentrated on the mechanism whereby hydroxyurea (HU) enhances the frequency of MTX resistance by virtue of gene amplification (Johnston & Schimke, in preparation) .
We conclude that the initial event in selective gene amplification, e.g. of DHFR genes, is a nonspecific overreplication of DNA. Inasmuch as DHFR is replicated in the first h of S-phase, it will have a high probability of being involved in the overreplication process. Various forms of recombination occur subsequently to generate chromosomal or extrachromosomal genes, and the rare cell with a productive recombination to generate a cell with increased DHFR enzyme activity will subsequently be selected. We wish to emphasize that the majority of the overreplicated DNA is unstable and will rapidly be lost in progeny that are not under selective pressure.
Overreplication of DNA and the generation of various of chromosomal abnormalities We are currently exploring the hypothesis that overreplication of DNA in a single cell cycle generates free-ended, double-stranded DNA that is highly recombinogenic (Schimke, 1984b Mouse L5178Y cells in continuous growth were treated for 6 h with 1.0mM hydroxyurea, following which media was replaced with regular media. Colcemid was added 12 h later and cells were sorted for DNA content after staining with Hoechst's 33342 stain. "Dull" cells are those at the lower end of the fluorescence intensity.
"Bright" cells are those at the high end of fluorescence intensity ('l 10 fluorescence units, See Figure 1 ). Two hundred metaphase spreads were examined for karyological abnormalities. somes with extrachromosomal chromosomal DNA, (c) chromosomal fragmentation, (d) endoreduplication. What is particularly important is that the cells with the chromosomal aberrations occur only among that subset of the cell population with a DNA content/cell that is greater than 2C. Similar results (i.e. increased DNA content/cell and chromosomal aberrations) are also generated when cells are treated with aphidicolin or cells treated in mid S-phase with UV light and carcinogens (Tlsty & Sherwood, in preparation Aver & Zetterberg (1984) those tumours that result in death are those that are aneuploid. Thus we suggest that a secondary process leading to lethal tumorigenesis is the generation of aneuploidy and the subsequent selection of certain cells from such populations with increased growth-metastatic potential. We suggest that this process results from loss of replication control (as opposed to growth control) such that overreplication of DNA occurs with the consequence of generation of aneuploidy. Among such consequences are, indeed, amplification of specific oncogenes, as observed both in continuous cell lines derived from tumours, as well as in tumour cell populations per se (see .
Our laboratory studies raise several questions concerning cancer and cancer treatment. Could not the heterogeneity observed in tumours result from the generation of aneuploidy, such heterogeneity itself resulting from imbalances in gene dosages, gene amplification, or recombinational inactivation-activation of specific genes? If there is indication that the answer to this question might be yes, then a major question follows: do not many of the cancer treatment modalities result in overreplication of DNA, the consequence of which is generation of chromosomal aberrations? Might such treatments convert relatively benign tumours into a state of aneuploidy and progression to more lethal form? Indeed, treatment of an experimental tumour with cancer chemotherapeutic agents has been shown to increase heterogeneity in DNA/cell (deVere White, 1983) .
